Discovery of Gene Fusions in Driver-Negative Cancer Samples From the National Cancer Institute-Molecular Analysis for Therapy Choice Screening Cohort
Technology and awareness of actionable fusions have improved since the NCI-MATCH trial. With AMP-based technology, we identified 142 patients with fusions not detected during NCI-MATCH screening, many potentially actionable. These striking data underscore the need to optimize the fusion-detection capabilities of genotyping assays used in precision medicine.
Authors
- Jo Anne Fordham (ORCID: https://orcid.org/0009-0004-7489-5799)
- Ting-Chia Chang (ORCID: https://orcid.org/0000-0001-6296-5797)
- Jeffrey Sklar (ORCID: https://orcid.org/0000-0001-5334-6070)
- Grace Kirkpatrick
- Beatrice Melli (ORCID: https://orcid.org/0000-0003-1366-2081)
- Chris Karlovich (ORCID: https://orcid.org/0000-0002-4617-2161)
- Lisa M. McShane (ORCID: https://orcid.org/0000-0001-8195-3206)
- Stefan T. Kaluziak (ORCID: https://orcid.org/0000-0002-7531-2602)
- Jinglan Wang
- A. John Iafrate (ORCID: https://orcid.org/0000-0002-7888-4067)
- P. Mickey Williams (ORCID: https://orcid.org/0000-0002-3309-5988)
- Guangxiao Yang (ORCID: https://orcid.org/0000-0003-2101-8579)
- Rashi Purohit (ORCID: https://orcid.org/0000-0001-6038-9570)
- Prinjali Kalyan (ORCID: https://orcid.org/0000-0003-2684-3789)
- Elizabeth Codd
Institutions
- Leidos (United States) (US)
- National Institutes of Health (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1200/po-24-00493
- Citations
- 3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.86
Funders
- Leidos
- National Cancer Institute